Mor Urology, Inc.

Newmarket, Ontario L3X1W1

0 studies enrolling now · 6 studies all time

What they study most

Benign Prostatic Hypertrophy, Bladder Cancer, Bladder Neoplasm, Carcinoma in Situ, Metastatic Prostate Cancer, Mycobacterium, Neoplasm Recurrence, Local, Prostate Cancer, Transitional Cell, Carcinoma

Studies at this site

• Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) — Completed
• Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer — Stopped early
• Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer — Stopped early
• Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy — Stopped early
• A Trial of Degarelix in Patients With Prostate Cancer — Completed
• Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) — Completed